Allterum Therapeutics Receives FDA Clearance for 4A10 Antibody Therapy in Pediatric Leukemia
Key Insights
Allterum Therapeutics (search) has received FDA clearance for its Investigational New Drug (IND) application for 4A10, a monoclonal antibody targeting CD127 (search) in patients with relapsed or refractory acute lymphoblastic leukemia.
The upcoming first-in-human clinical trial will evaluate the safety, tolerability, pharmacokinetics, and preliminary efficacy of 4A10 in pediatric patients who have failed available therapies.
4A10 works by binding to CD127 (search) and inhibiting IL-7-induced signaling while inducing cell-mediated killing through antibody-dependent cellular cytotoxicity and phagocytosis.
Allterum Therapeutics (search) has achieved a significant regulatory milestone with FDA clearance of its Investigational New Drug (IND) application for 4A10, a monoclonal antibody designed to treat children with relapsed or refractory acute lymphoblastic leukemia (ALL). This clearance enables the Houston-based biotechnology company to advance into first-in-human clinical trials for what represents a critical unmet medical need in pediatric oncology.
Clinical Development Program
The upcoming clinical trial will evaluate the safety, tolerability, pharmacokinetics, and preliminary efficacy of 4A10 in patients with relapsed or refractory ALL. According to Dr. Yan Moore, Chief Executive Officer of Allterum Therapeutics (search), "FDA clearance of 4A10 marks a transformational step for Allterum as we transition into a clinical-stage company. Our mission is deeply personal - we are determined to bring forward best-in-class precision medicines that not only advance science but also bring new hope to children and families who have been waiting far too long for better options."
Dr. Eric Schafer, a national pediatric leukemia thought leader serving as study chair, emphasized the urgent need for new therapeutic approaches: "Children and young adults with relapsed ALL urgently need new therapeutic approaches. We are eager to begin this first-in-human trial of 4A10 and explore its potential to address a critical gap in treatment for these vulnerable patients."
Mechanism of Action and Preclinical Data
4A10 is a monoclonal antibody with a human Immunoglobulin G Subclass 1 (IgG1) backbone that specifically binds to CD127 (search), also known as Interleukin-7 receptor alpha subunit (IL-7Rα). CD127 serves as a key component of both the IL-7 receptor and the Thymic Stromal Lymphopoietin Receptor (TSLPR), which are expressed on T-ALL and pre-B-ALL cells, respectively.
Following binding to CD127 (search), 4A10 inhibits IL-7-induced signaling and induces cell-mediated killing through Antibody-Dependent Cellular Cytotoxicity (ADCC) and Antibody-Dependent Cellular Phagocytosis (ADCP). Preclinical studies demonstrated potent anti-leukemic activity and a favorable safety profile, supporting advancement into first-in-human clinical trials.
Addressing Critical Medical Need
ALL represents the most common pediatric cancer, and patients who have failed available therapies face a poor prognosis with limited treatment options. Dr. Atul Varadhachary, Chairman of the Board of Directors at Allterum Therapeutics (search), noted that "ALL is the most common pediatric cancer and patients who have failed available therapies have a poor prognosis and few options. This IND clearance validates our strategy and moves us closer to providing therapies that can truly change the trajectory in this important disease."
Financial Support and Company Background
The development of 4A10 has received additional support through a $1 million Small Business Innovation Research (SBIR) grant from the National Cancer Institute (NCI). This funding will support the clinical development efforts for the therapeutic antibody, enabling the company to conduct preclinical studies and prepare for clinical trials assessing safety and efficacy in pediatric patients.
Allterum Therapeutics (search) is a Houston-based clinical-stage biotechnology company advancing a pipeline of innovative precision oncology and inflammation drugs. The company leverages cutting-edge science and strategic collaborations to accelerate the development of transformative therapies for children and adults with high unmet medical needs.